ClinicalTrials.gg
TerminatedNCT04208698Updated Aug 10, 2021Results posted

A Scintigraphy Study in Adults With Diabetic Gastroparesis

A Phase 2 interventional study of CIN-102 Dose 1 and CIN-102 Dose 2 in Diabetic Gastroparesis, sponsored by CinDome Pharma, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Trial was terminated due to the impact of COVID-19 on trial activities.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
128th of 136
2 · median 36
Started
2020
with 11 others
Phase 2
38 of 184
none open now
Registered
113th of 184
by date
Lead sponsor
4 of 184
CinDome Pharma, Inc.

Among the 184 studies in Gastroparesis with a site in United States, this one is the 128th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2020, is one of 38 in phase 2, and was the 113th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.

Read the detailed description

This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis. The population for this study is adult patients 18 to 70 years old with Type 1 or Type 2 diabetes and a diagnosis of diabetic gastroparesis. The study will consist of two cohorts with approximately 15 subjects in each cohort.

03

Conditions studied

  • Diabetic Gastroparesis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 to 70 years old, inclusive.
  • Type 1 or Type 2 diabetes mellitus, according to American Diabetes Association criteria
  • Current diagnosis of diabetic gastroparesis.
  • (BMI) between 18 and 40 kg/m2, inclusive.
  • Glycosylated level \<11% at Screening.
  • Willing to abstain from tobacco or nicotine-containing product use after midnight on the day of the DAS test and throughout the time that gastric emptying is being imaged.
  • Willing to abstain from grapefruit, grapefruit products, star fruit, star fruit products, and Seville oranges from 72 hours prior to the Randomization Visit until end of study.

Exclusion criteria

Exclusion Criteria:

  • History of, or current, arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, and Torsades de Pointes. Patients with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded.
  • Clinically significant bradycardia with a resting heart rate under 50 beats per minute, sinus node dysfunction, or heart block.
  • Prolonged heart rate- interval using Fridericia's formula (QTcF) (QTcF >450 msec for males or QTcF >470 msec for females) based on the average of triplicate ECGs.
  • A personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias or family history of sudden death.
  • Evidence (based on Screening or Baseline assessments) or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies); surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that resolved or has been in remission for >5 years prior to the Screening Visit); or any condition that, in the Investigator's opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug.
  • History of prolactin-releasing pituitary tumor (ie, prolactinoma).
  • Allergic to egg or intolerant to gluten.
  • History of alcoholism or drug abuse within 2 years prior to dosing as defined by the , 4th Edition.
  • Known or suspected gastric outlet obstruction (eg, peptic stricture) or other gastrointestinal mechanical obstruction.
  • Known history or current diagnosis of intestinal malabsorption or pancreatic exocrine disease.
  • History or presence of any medical condition or psychiatric disease, which, in the opinion of the Investigator, could interfere with the conduct of the study or would put the patient at unacceptable risk.
  • Judged by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluation, to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of the study outcomes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    CIN-102 Tablets Dose 1

    CIN-102 tablets by mouth twice daily for 14 days

    Drug: CIN-102 Dose 1

  • Placebo comparator
    Placebo for CIN-102 Dose 1

    Placebo tablets by mouth twice daily for 14 days

    Drug: Placebo for CIN-102

  • Experimental
    CIN-102 Dose 2

    CIN-102 tablets by mouth twice daily for 14 days

    Drug: CIN-102 Dose 2

  • Placebo comparator
    Placebo for CIN-102 Dose 2

    Placebo tablets by mouth twice daily for 14 days

    Drug: Placebo for CIN-102

Interventions

  • DrugCIN-102 Dose 1

    Drug pages: CIN-102 · Deudomperidone

    Deuterated domperidone (deudomperidone)

  • DrugCIN-102 Dose 2

    Drug pages: CIN-102 · Deudomperidone

    Deuterated domperidone (deudomperidone)

  • DrugPlacebo for CIN-102

    Placebo

06

What researchers measure

Primary outcomes

  1. To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.

    Time frame: Baseline to Day 14

Secondary outcomes

  1. To Evaluate the Incidence of Treatment-emergent Adverse Effects as Measured by Safety Laboratory Data and Patient Reported Events.

    Time frame: Screening to Day 20

  2. To Assess the Effect of CIN-102 on Antral Contractility as Measured by Dynamic Antral Scintigraphy (DAS), a Non-invasive Technique for the Assessment of Post-prandial Gastric Contractions Will be Used to Evaluate Antral Motility.

    Time frame: Baseline to Day 14

  3. To Assess the Effect of CIN-102 on Gastric Accommodation to be Evaluated Using Data Captured During the Total-stomach Gastric Emptying Study to Measure Food Retention in the Stomach During the First Two Post-prandial Hours.

    Time frame: Baseline to Day 14

  4. To Asses the Change From Baseline in ANMS GCSI-DD Total Scores

    Time frame: Day -14 to 14

  5. To Assess the Change From Baseline in ANMS GCSI-DD Subscale Scores

    Time frame: Day -14 to 14

  6. To Assess the Change From Baseline in Symptom Severity as Measured by the PAGI-SYM

    Time frame: Baseline to Day 14

  7. To Assess the Change in Baseline of the Clinical Grading Assessment Scale

    Time frame: Baseline to Day 14

07

Results

Posted Aug 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneScreening PeriodCIN-102 Tablets Dose 1Placebo for CIN-102 Dose 1CIN-102 Dose 2Placebo for CIN-102 Dose 2
Started20000
Completed00000
Not completed20000

Outcome measures

PrimaryTo Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.
Time frame:
Baseline to Day 14

No measurements were reported for this outcome.

SecondaryTo Evaluate the Incidence of Treatment-emergent Adverse Effects as Measured by Safety Laboratory Data and Patient Reported Events.
Time frame:
Screening to Day 20

No measurements were reported for this outcome.

SecondaryTo Assess the Effect of CIN-102 on Antral Contractility as Measured by Dynamic Antral Scintigraphy (DAS), a Non-invasive Technique for the Assessment of Post-prandial Gastric Contractions Will be Used to Evaluate Antral Motility.
Time frame:
Baseline to Day 14

No measurements were reported for this outcome.

SecondaryTo Assess the Effect of CIN-102 on Gastric Accommodation to be Evaluated Using Data Captured During the Total-stomach Gastric Emptying Study to Measure Food Retention in the Stomach During the First Two Post-prandial Hours.
Time frame:
Baseline to Day 14

No measurements were reported for this outcome.

SecondaryTo Asses the Change From Baseline in ANMS GCSI-DD Total Scores
Time frame:
Day -14 to 14

No measurements were reported for this outcome.

SecondaryTo Assess the Change From Baseline in ANMS GCSI-DD Subscale Scores
Time frame:
Day -14 to 14

No measurements were reported for this outcome.

SecondaryTo Assess the Change From Baseline in Symptom Severity as Measured by the PAGI-SYM
Time frame:
Baseline to Day 14

No measurements were reported for this outcome.

SecondaryTo Assess the Change in Baseline of the Clinical Grading Assessment Scale
Time frame:
Baseline to Day 14

No measurements were reported for this outcome.

Adverse events

Collected over Approximately one month.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CIN-102 Tablets Dose 1———
Placebo for CIN-102 Dose 1———
CIN-102 Dose 2———
Placebo for CIN-102 Dose 2———

Baseline characteristics

Two patients entered the Screening Period. No patients were randomized to the Treatment Period.

Age, Categorical
Age, Categorical(Participants)Screening PeriodCIN-102 Tablets Dose 1Placebo for CIN-102 Dose 1CIN-102 Dose 2Placebo for CIN-102 Dose 2Total
<=18 years0————0
Between 18 and 65 years2————2
>=65 years0————0
Sex: Female, Male
Sex: Female, Male(Participants)Screening PeriodCIN-102 Tablets Dose 1Placebo for CIN-102 Dose 1CIN-102 Dose 2Placebo for CIN-102 Dose 2Total
Female1————1
Male1————1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Screening PeriodCIN-102 Tablets Dose 1Placebo for CIN-102 Dose 1CIN-102 Dose 2Placebo for CIN-102 Dose 2Total
Hispanic or Latino1————1
Not Hispanic or Latino1————1
Unknown or Not Reported0————0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Screening PeriodCIN-102 Tablets Dose 1Placebo for CIN-102 Dose 1CIN-102 Dose 2Placebo for CIN-102 Dose 2Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White200002
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Screening PeriodCIN-102 Tablets Dose 1Placebo for CIN-102 Dose 1CIN-102 Dose 2Placebo for CIN-102 Dose 2Total
United States2————2
08

Study locations

1 site
  • Research Site
    El Paso, Texas 79905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Mar 2020, 1 month.

Results were first posted in Aug 2021, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2019
First posted
Dec 23, 2019
StartActual
Feb 17, 2020
Primary completionActual
Mar 31, 2020
CompletionActual
Mar 31, 2020
Results first posted
Aug 10, 2021
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04208698
Lead sponsor
CinDome Pharma, Inc.
Responsible party
Sponsor
First posted
Dec 23, 2019
Start date
Feb 17, 2020
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Results posted
Aug 10, 2021
Last update
Aug 10, 2021

Study contacts

Brian Murphy, MD, MPH
study director · CinRx Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CIN-102 · Deudomperidone

Start the discussion